Beverly Davidson

Beverly L. Davidson is an American geneticist. She is the director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics at Children's Hospital of Philadelphia. In this role, she investigates gene therapy for neurodegenerative diseases, specifically Huntington's.

Beverly Davidson
Academic background
EducationBS, 1981, Nebraska Wesleyan University
PhD, Biological Chemistry, 1987, University of Michigan
ThesisThe Genetic Basis of Hypoxanthine Guanine Phosphoribosyltransferase Deficiency States in Humans (1988)
Academic work
InstitutionsPerelman School of Medicine at the University of Pennsylvania
Children's Hospital of Philadelphia
University of Iowa

In 2019, Davidson was elected a member of the National Academy of Medicine for her "being on the forefront of developing innovative therapies and medicines for fatal, inherited brain disorders, which are engineered to either remove toxic proteins or replace missing proteins, and for improving or preventing disease progression."

Early life and education

Davidson earned her Bachelor of Science degree from Nebraska Wesleyan University and her PhD in Biological Chemistry from the University of Michigan.[1] Davidson's thesis was conducted under the guidance of William Kelley and titled "The Genetic Basis of Hypoxanthine Guanine Phosphoribosyltransferase Deficiency States in Humans."[2]

Career

Upon completing her medical degree, Davidson joined the faculty at the University of Iowa's Department of Internal Medicine. In this role, she led the first study which used small RNA molecules packed into viruses to treat mice with an inherited disease. When they injected interfering RNA into the brains of the mice, their motor coordination improved, brain morphology was restored, and pathology decreased.[3] This subsequently proved that gene therapy in mice could prevent the physical symptoms and neurological damage related to Huntington's disease.[4] The following year, as the Roy J. Carver Biomedical Research Chair, her research team used RNA to reduce levels of the HD protein in mice which significantly improved the movement and neurological abnormalities normally associated with the disease.[5] In recognition of her accomplishments, Davidson was the recipient of a 2007 Regents Award for Faculty Excellence from the university.[6]

In her final year with the University of Iowa, Davidson co-launched Spark Therapeutics with Jean Bennett to "develope gene-based medicines for a wide range of debilitating diseases" in collaboration with the Children's Hospital of Philadelphia (CHOP).[7] She subsequently left the University of Iowa in 2014 to accept a position as the director of the Center for Cellular and Molecular Therapeutics at CHOP.[8] As the director, Davidson helped Spark launch their first gene therapy program targeting a disease of the central nervous system.[9] Following this, Davidson was elected to the American Academy of Arts and Sciences[10] and named director of CHOP's underground clinical manufacturing facility in the Colket Translational Research Building.[11]

As the Chief Scientific Strategy Officer and Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Davidson elected Vice President of the Board of Directors for the American Society of Gene and Cell Therapy.[12] In 2019, Davidson was elected a member of the National Academy of Medicine for her "being on the forefront of developing innovative therapies and medicines for fatal, inherited brain disorders, which are engineered to either remove toxic proteins or replace missing proteins, and for improving or preventing disease progression."[13]

References
  1. "Beverly L. Davidson, Ph.D." med.upenn.edu. Retrieved November 16, 2020.
  2. "Beverly L. Davidson, Ph.D. 88". medicine.umich.edu. Retrieved November 16, 2020.
  3. Shouse, Ben (June 7, 2004). "RNA Fights Brain Disease in Mice". sciencemag.org. Retrieved November 16, 2020.
  4. "Combination Of Gene Therapy And Gene Silencing Prevents Neurodegenerative Disease". hum-molgen.org. June 6, 2004. Retrieved November 16, 2020.
  5. Brown, Jennifer (May 4, 2005). "U. Iowa researchers improve Huntington's disease symptoms in mice". innovations-report.com. Retrieved November 16, 2020.
  6. Riehl, Nicole (August 29, 2007). "Six UI professors win regents awards for faculty excellence". news-releases.uiowa.edu. Archived from the original on June 20, 2008. Retrieved November 16, 2020.
  7. "Spark Therapeutics Launched with $50 Million in Financing to Advance Late- and Mid-Stage Gene Therapy Programs with Clinical Proof of Concept". prnewswire.com. October 22, 2013. Retrieved November 16, 2020.
  8. "Gene Therapy Expert Beverly Davidson, PhD, to Join CHOP". chop.edu. April 1, 2014. Retrieved November 16, 2020.
  9. "Spark Therapeutics Announces SPK-TPP1, Its First Program Targeting Neurodegenerative Disease". sparktx.com. November 11, 2015. Retrieved November 16, 2020.
  10. "Beverly Davidson, Samuel Freeman and Pamela Grossman: American Academy of Arts and Sciences". almanac.upenn.edu. April 25, 2017. Retrieved November 16, 2020.
  11. DiStefano, Joseph N. (November 1, 2018). "CHOP set to open its gene-therapy factory". Philadelphia Inquirer. Archived from the original on November 8, 2020. Retrieved November 16, 2020.
  12. "Children's Hospital of Philadelphia Announces Election of Beverly Davidson to Vice President of the Board of Directors, American Society of Gene and Cell Therapy". prnewswire.com. April 9, 2019. Retrieved November 16, 2020.
  13. "Beverly Davidson, PhD, elected to the National Academy of Medicine". eurekalert.org. October 21, 2019. Retrieved November 16, 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.